Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™Read More
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational HighlightsRead More
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in OctoberRead More
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough SummitRead More